CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $20.37B, above the global median of $1.18B
- FinancialsAltman Z-Score 4.88: safe zone
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.31%Above 5Y avg (0.90%)
Annual Rate
USD 2.76Paid quarterly
Payout Ratio
30.8%Sustainable
Paying Dividends
25 yr
Payback Period
80.8 yr
Last Ex-Dividend
Sep 4, 2026
Last Payment
Sep 25, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
20.37BUSDvs all stocks (USD)
Trailing P/E
25.62xvs Medical Devices peers
Revenue (TTM)
6.04BUSDvs all stocks (USD)
Profit Margin
13.33%vs Medical Devices peers
Beta
0.9140xvs all stocks
52-Week Change
-14.16%vs all stocks
Forward Annual Dividend Yield
1.31%vs all stocks
Market Capitalization
20.37BUSDvs all stocks (USD)
Enterprise Value
21.95BUSDvs all stocks (USD)
Trailing P/E
25.62xvs Medical Devices peers
Forward P/E
17.13xvs Medical Devices peers
PEG Ratio
1.76xvs Medical Devices peers
Price to Sales (TTM)
3.39xvs Medical Devices peers
Price to Book (MRQ)
2.84xvs Medical Devices peers
Enterprise to Revenue
3.63xvs Medical Devices peers
Enterprise to EBITDA
13.38xvs Medical Devices peers
Gross Margin
45.84%vs Medical Devices peers
Profit Margin
13.33%vs Medical Devices peers
Operating Margin
19.15%vs Medical Devices peers
Return on Assets (TTM)
6.80%vs Medical Devices peers
Return on Equity (TTM)
11.39%vs Medical Devices peers
Revenue (TTM)
6.04BUSDvs all stocks (USD)
Revenue per Share (TTM)
61.61USDUpdated Sep 28, 2026Quarterly Revenue Growth
7.30%vs Medical Devices peers
Gross Profit (TTM)
2.68BUSDvs all stocks (USD)
EBITDA (TTM)
1.64BUSDvs all stocks (USD)
Net Income (TTM)
805.00MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
12.80%vs Medical Devices peers
Operating Cash Flow (TTM)
1.29BUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
798.86MUSDvs all stocks (USD)
Forward Annual Dividend Rate
2.76USDUpdated Sep 28, 2026Forward Annual Dividend Yield
1.31%vs all stocks
Trailing Annual Dividend Rate
2.58USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
1.23%vs all stocks
5-Year Average Dividend Yield
0.90%vs all stocks
Payout Ratio
30.81%vs Medical Devices peers
Minority Interest (Equity)
13.60MUSDFY2026 · Mar 31, 2026Revenue
5.94BUSDFY2026 · Mar 31, 2026Cost of Goods Sold
3.31BUSDFY2026 · Mar 31, 2026Gross Profit
2.63BUSDFY2026 · Mar 31, 2026Operating Income
1.11BUSDvs all stocks (USD)
Pre-tax Income
1.05BUSDFY2026 · Mar 31, 2026Income Tax Expense
262.20MUSDFY2026 · Mar 31, 2026Net Income
785.10MUSDFY2026 · Mar 31, 2026EBIT
1.11BUSDFY2026 · Mar 31, 2026EBITDA (Income Statement)
1.60BUSDFY2026 · Mar 31, 2026Research & Development
112.90MUSDFY2026 · Mar 31, 2026Selling, General & Administrative
1.41BUSDFY2026 · Mar 31, 2026Non-operating Interest Income
9.80MUSDFY2026 · Mar 31, 2026Non-operating Interest Expense
60.70MUSDFY2026 · Mar 31, 2026EPS (Basic)
7.97USDFY2026 · Mar 31, 2026EPS (Diluted)
7.93USDFY2026 · Mar 31, 2026Basic Shares Outstanding
98.20MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
98.20MSharesFY2026 · Mar 31, 2026Net Income from Continuing Operations
785.10MUSDFY2026 · Mar 31, 2026Minority Interests (P&L)
-2.80MUSDFY2026 · Mar 31, 2026Operating Cash Flow
1.29BUSDFY2026 · Mar 31, 2026Free Cash Flow
931.80MUSDFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
439.60MUSDFY2026 · Mar 31, 2026Starting Profit (CF Statement)
785.10MUSDFY2026 · Mar 31, 2026Depreciation & Amortization
486.50MUSDFY2026 · Mar 31, 2026Deferred Taxes (CF)
-16.90MUSDFY2026 · Mar 31, 2026Stock-based Compensation
61.70MUSDFY2026 · Mar 31, 2026Other Non-cash Items
-5.40MUSDFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-25.10MUSDFY2026 · Mar 31, 2026Change in Accounts Payable (CF)
51.10MUSDFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-46.70MUSDFY2026 · Mar 31, 2026Capital Expenditures
-358.50MUSDFY2026 · Mar 31, 2026Net Acquisitions
-20.10MUSDFY2026 · Mar 31, 2026Purchase of Investments
-134.00MUSDFY2026 · Mar 31, 2026Sale of Investments
0.00USDFY2026 · Mar 31, 2026Other Investing Activity
100.00KUSDFY2026 · Mar 31, 2026Net Investing Cash Flow
-512.50MUSDFY2026 · Mar 31, 2026Long-term Debt Issuance
3.00MUSDFY2026 · Mar 31, 2026Long-term Debt Payments
-125.00MUSDFY2026 · Mar 31, 2026Common Stock Repurchase
-235.50MUSDFY2026 · Mar 31, 2026Common Dividends Paid
-241.80MUSDFY2026 · Mar 31, 2026Other Financing Charges
-1.80MUSDFY2026 · Mar 31, 2026Net Financing Cash Flow
-601.10MUSDFY2026 · Mar 31, 2026Shares Outstanding
97.46MSharesUpdated Sep 28, 2026Float Shares
97.08MSharesUpdated Sep 28, 2026Shares Short
2.79MSharesUpdated Sep 28, 2026Short Ratio
4.62daysvs all stocks
Short % of Shares Outstanding
2.87%vs all stocks
% Held by Insiders
0.31%vs all stocks
% Held by Institutions
100.95%vs all stocks
Total Cash (MRQ)
482.30MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.95USDUpdated Sep 28, 2026Total Debt (MRQ)
2.04BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2831xvs Medical Devices peers
Current Ratio (MRQ)
1.91xvs Medical Devices peers
Book Value per Share (MRQ)
73.92USDUpdated Sep 28, 2026Total Assets
10.74BUSDvs all stocks (USD)
Total Current Assets
2.39BUSDFY2026 · Mar 31, 2026Total Liabilities
3.54BUSDFY2026 · Mar 31, 2026Total Non-current Assets
8.34BUSDFY2026 · Mar 31, 2026Total Non-current Liabilities
2.40BUSDFY2026 · Mar 31, 2026Total Current Liabilities
1.15BUSDFY2026 · Mar 31, 2026Cash & Cash Equivalents
439.60MUSDFY2026 · Mar 31, 2026Accounts Receivable
1.09BUSDFY2026 · Mar 31, 2026Inventory
631.80MUSDFY2026 · Mar 31, 2026Accounts Payable
338.80MUSDFY2026 · Mar 31, 2026Short-term Debt
154.70MUSDFY2026 · Mar 31, 2026Deferred Revenue
59.10MUSDFY2026 · Mar 31, 2026Other Current Liabilities
271.50MUSDFY2026 · Mar 31, 2026Long-term Debt
1.93BUSDFY2026 · Mar 31, 2026Other Non-current Liabilities
22.00MUSDFY2026 · Mar 31, 2026Common Stock (Book)
4.28BUSDFY2026 · Mar 31, 2026Retained Earnings
3.02BUSDFY2026 · Mar 31, 2026Total Shareholders' Equity
7.20BUSDvs all stocks (USD)
52-Week Low
195.14USDUpdated Sep 28, 202652-Week High
269.44USDUpdated Sep 28, 202652-Week Change
-14.16%vs all stocks
Beta
0.9140xvs all stocks
50-Day MA
224.30USDUpdated Sep 28, 2026200-Day MA
229.30USDUpdated Sep 28, 2026Avg 10-Day Volume
685.66KSharesUpdated Sep 28, 2026Avg 30-Day Volume
625.21KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
8.19USDUpdated Sep 28, 2026Other Income / Expense
-7.60MUSDFY2026 · Mar 31, 20266 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
Where is this company structurally exposed?
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.88: safe zoneNotable
Altman Z-Score: 4.88
High earnings qualityNotable
Earnings Quality Score: 1.87
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $20.37B, above the global median of $1.18BNotable
Market cap (USD): 20,370,697,007Global Median: 1,180,223,658.953
Revenue is $6.04B, above the global median of $548.88MNotable
Revenue (USD): 6,037,499,904Global Median: 548,883,780.48
Levered free cash flow is $798.86M, above the global median of $18.73MNotable
Levered free cash flow (USD): 798,862,528Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
United Therapeutics Corporation
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Viatris Inc.
Tier 1ProductionApproval-Gated PipelineRule
Torrent Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zimmer Biomet Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Koninklijke Philips N.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sonova Holding AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Incyte Corporation
Tier 1ProductionApproval-Gated PipelineRule
Insmed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sino Biopharmaceutical Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Roivant Sciences Ltd
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Afya Ltd.
5 interpretationsCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthClose Below 40W SMA With ProfitabilityMulti-Year FCF With Growth And Margin
Fortune Electric Co., Ltd.
5 interpretationsCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthClose Below 40W SMA With ProfitabilityMulti-Year FCF With Growth And Margin
Elixirr International plc
6 interpretationsReceivables Heavy and GrowingCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthClose Below 40W SMA With ProfitabilityMulti-Year FCF With Growth And Margin